Diagnostic and prognostic research, 6(1):14 Diagnostic and prognostic research 6, 14 (2022). doi:10.1186/s41512-022-00128-8 Diagnostic and Prognostic Research
Lancet Oncology, 20, 1273-1285 Lancet oncology, 20(9), 1273-1285. Elsevier Science The Lancet Oncology, 20(9), 1273-1285 PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X The Lancet Oncology Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC Lancet Oncology, 20, 9, pp. 1273-1285
BMC Cancer, 19:901. BioMed Central BMC Cancer, Vol 19, Iss 1, Pp 1-13 (2019) De Haan, R, Van Werkhoven, E, Peulen, H M U, Sonke, G S, Elkhuizen, P, Van Den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, Van Triest, B & Verheij, M 2019, ' Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib ', BMC Cancer, vol. 19, no. 1, 901 . https://doi.org/10.1186/s12885-019-6121-3 BMC Cancer, 19(1). BioMed Central BMC Cancer, 19 BMC Cancer, 19(1):901. BioMed Central BMC cancer, 19(1):901. BioMed Central BMC Cancer